---
title: Maudsley Prescribing Guidelines - Antipsychotic Prescribing
organization: Maudsley Hospital / South London and Maudsley NHS Foundation Trust
year: 2024
category: schizophrenia
---

# Maudsley Prescribing Guidelines: Antipsychotic Medications

## Choice of Antipsychotic

### First-Episode Psychosis:
- **Preference**: Second-generation antipsychotics (SGAs) due to lower EPS risk
- **Recommended SGAs**: Risperidone, olanzapine, quetiapine, aripiprazole
- **Start low**: Use minimum effective dose
- **Avoid**: High-dose typical antipsychotics (FGAs) first-line

### Chronic Schizophrenia:
- Consider prior response and tolerability
- If no prior history: Choose based on side effect profile
- Patient preference important

## Dosing Principles

### Target Dose Ranges (Schizophrenia):
| Medication | Starting Dose | Target Dose | Maximum Dose |
|------------|---------------|-------------|--------------|
| **Risperidone** | 1-2 mg/day | 4-6 mg/day | 8 mg/day |
| **Olanzapine** | 5-10 mg/day | 10-20 mg/day | 20 mg/day |
| **Quetiapine** | 50 mg BID | 300-800 mg/day | 800 mg/day |
| **Aripiprazole** | 10-15 mg/day | 10-30 mg/day | 30 mg/day |
| **Paliperidone** | 6 mg/day | 6-12 mg/day | 12 mg/day |
| **Lurasidone** | 40 mg/day | 80-160 mg/day | 160 mg/day |
| **Haloperidol** | 1-2 mg/day | 3-10 mg/day | 20 mg/day |

### General Principles:
- **"Start low, go slow"** - especially in first episode, elderly
- Wait 4-6 weeks at therapeutic dose before declaring inadequate response
- Avoid polypharmacy (multiple antipsychotics) except during cross-titration

## Treatment-Resistant Schizophrenia (TRS)

### Definition:
- Inadequate response to ≥2 antipsychotics (different classes) at adequate dose for ≥6 weeks each
- Persistent positive symptoms despite treatment

### Gold Standard Treatment:
**Clozapine**
- Most effective antipsychotic for TRS
- Start 12.5-25 mg/day, titrate slowly to 300-450 mg/day
- Target plasma level: 350-600 ng/mL (some suggest up to 1000 ng/mL)
- MANDATORY monitoring: ANC (agranulocytosis risk)

### Clozapine Augmentation (if partial response):
1. **Amisulpride** (limited evidence)
2. **Aripiprazole** (limited evidence)
3. **ECT** (for catatonia or severe refractory cases)
4. **Optimize clozapine level** before adding second agent

## Rapid Tranquilization (RT) / Acute Agitation

### Preferred Options:
1. **Oral route first**: Lorazepam 1-2 mg PO ± risperidone/olanzapine
2. **IM options if needed**:
   - Lorazepam 1-2 mg IM (safe, lower EPS)
   - Haloperidol 5 mg IM ± lorazepam 1-2 mg IM
   - Olanzapine 5-10 mg IM (do NOT combine with benzodiazepines IM - respiratory depression)
   - Aripiprazole 9.75 mg IM

### Maximum Doses (24 hours):
- Haloperidol: 18 mg IM/day
- Olanzapine: 20 mg IM/day
- Lorazepam: 4 mg IM/day

### Monitoring:
- Vital signs (BP, HR, RR) every 15-30 minutes
- ECG if cardiac risk factors or QTc-prolonging drugs used
- Observe for EPS, dystonia, oversedation

## Long-Acting Injectable (LAI) Antipsychotics

### Indications:
- Non-adherence or preference for LAI
- Relapse prevention
- Patient choice

### Commonly Used LAIs:
| Medication | Formulation | Dosing Interval |
|------------|-------------|-----------------|
| **Paliperidone palmitate** | Monthly / Quarterly | Every 4 weeks or every 3 months |
| **Aripiprazole monohydrate** | Monthly | Every 4 weeks |
| **Risperidone** | Bi-weekly | Every 2 weeks |
| **Olanzapine pamoate** | Bi-weekly/monthly | Every 2-4 weeks |
| **Haloperidol decanoate** | Monthly | Every 4 weeks |
| **Fluphenazine decanoate** | Bi-weekly/monthly | Every 2-4 weeks |

### Initiation:
- Oral trial first to assess tolerability (except paliperidone - can initiate without oral trial in some formulations)
- Overlap oral for 1-2 doses while LAI loads

## Metabolic Monitoring

### Baseline:
- Weight, BMI, waist circumference
- Fasting glucose (or HbA1c)
- Fasting lipids
- Blood pressure

### Follow-up:
- Weight: Weekly x 6 weeks, then monthly x 3 months, then quarterly
- Glucose/lipids: 3 months, then annually
- BP: 3 months, then annually

### High Metabolic Risk Antipsychotics:
- Clozapine > Olanzapine > Quetiapine > Risperidone > Paliperidone
- Lower risk: Aripiprazole, lurasidone, ziprasidone, asenapine, haloperidol

## Movement Disorder Monitoring

### Baseline and Every 6-12 Months:
- **AIMS** (Abnormal Involuntary Movement Scale) for tardive dyskinesia
- **SAS** (Simpson-Angus Scale) for parkinsonism
- Assess for akathisia, dystonia

### Management of EPS:
- **Acute dystonia**: Benztropine 1-2 mg IM/PO or diphenhydramine 25-50 mg IM
- **Parkinsonism**: Reduce dose or switch; anticholinergics (benztropine, trihexyphenidyl)
- **Akathisia**: Reduce dose; propranolol 20-80 mg/day; benzodiazepines
- **Tardive dyskinesia**: Stop offending agent if possible; consider VMAT2 inhibitors (valbenazine, deutetrabenazine)

## Switching Antipsychotics

### Cross-Titration:
- Gradually increase new antipsychotic while tapering old
- Faster switching acceptable if urgency or high-risk medications (clozapine - restart titration)

### Avoid Abrupt Discontinuation:
- Risk of withdrawal (insomnia, nausea, cholinergic rebound with clozapine/olanzapine/quetiapine)

## Sources
- Taylor DM, et al. The Maudsley Prescribing Guidelines in Psychiatry (14th Edition). 2024.
- Maudsley Hospital Clinical Guidelines
